Morphologic, prognostic, and immunosuppression therapy response distribution
| Characteristic . | AA . | Post-AA MDS . | Hypoplastic MDS . | MDS . |
|---|---|---|---|---|
| Marrow cellularity | Decreased | Mostly Increased | Decreased | Normal/ increased |
| Abnormal neutrophils | − | possible | + | + |
| Abnormal megakaryocytes | − | − | + | + |
| Blasts | Absent | Increased | +/− | Often increased |
| Megakaryocytes | Absent/decreased | Absent | + | + |
| Fibrosis | − | − | Occasional | Occasional |
| Progression | ∼10% | + | >25% | >25% |
| Response to IST | ++ | − | + | − |
| PNH defect | ∼30% | Possible | Rare | Absent |
| T-cell activation | + | + | + | +/− |
| LGL | − | − | + | + |
| Characteristic . | AA . | Post-AA MDS . | Hypoplastic MDS . | MDS . |
|---|---|---|---|---|
| Marrow cellularity | Decreased | Mostly Increased | Decreased | Normal/ increased |
| Abnormal neutrophils | − | possible | + | + |
| Abnormal megakaryocytes | − | − | + | + |
| Blasts | Absent | Increased | +/− | Often increased |
| Megakaryocytes | Absent/decreased | Absent | + | + |
| Fibrosis | − | − | Occasional | Occasional |
| Progression | ∼10% | + | >25% | >25% |
| Response to IST | ++ | − | + | − |
| PNH defect | ∼30% | Possible | Rare | Absent |
| T-cell activation | + | + | + | +/− |
| LGL | − | − | + | + |
IST, immunosuppressive therapy; LGL, large granular lymphocyte leukemia; +, presence and/or response; −, negative response or absence.